


SERMO REALTIME: AFPA/BPC BIOSIMILAR NAMING SURVEY


Survey fielded of 509 respondents in October 2016 with SERMO by AfPA and BPC.
**SERMO is the largest global social network exclusively for doctors.*



SERMO REALTIME: AFPA/BPC BIOSIMILAR NAMING SURVEY

Question 1

FDA has employed two methods for the naming of biosimilars – the first, i.e. “filgrastim-sndz”, uses the international nonproprietary name (INN) for the drug and a four letter suffix that denotes the manufacturer, in this case, Sandoz. The second, i.e., “infliximab-dyyb” also uses the INN for the drug but includes a random four letter suffix. Which type of suffix is preferable to you?




Takeaway:
Overwhelming support for
“Meaningful suffix”
(406 of 509 respondents)

SERMO REALTIME: AFPA/BPC BIOSIMILAR NAMING SURVEY


Question 2

Which of the following statements do you agree with the most?



SERMO REALTIME: AFPA/BPC BIOSIMILAR NAMING SURVEY

Additional respondent info: Question 1



N=509